

Dr Anna Koumarianou

Consultant in Medical Oncology

✉, Hematology Oncology Unit

Fourth Department of Internal Medicine

Attikon University General Hospital

National Kapodistrian University of Athens, Medical School

Rimini 1, 12462, Athens, Greece ☎ +30 6932 281861 ✉ akoumari@yahoo.com

Previous GMC Registration Number (full): 4149633

Permission to practice Medical Oncology in Greece: Prefecture of Athens, Municipality of Health and Public Health: 5273/01.06.2001

Licence to practice Medicine in Italy after examination (State Exam, Medical School Bologna University 1991).

Profile

I am a Consultant in Medical Oncology and Head of Hematology-Oncology Unit, and Oncology Clinical Trials Unit at Fourth Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Attikon University Hospital. I am responsible for the delivery of chemotherapy and novel anticancer agents to patients with the whole spectrum of malignant diseases; specific interests lie in breast cancer and neuroendocrine tumours.

I am co-leader in the National Centre of Excellence in Neuroendocrine Tumours. The Centre is accredited by the Euracan and by the European Neuroendocrine Tumor Society and holds a multidisciplinary tumor board meeting via zoom every 2 weeks.

I am co-leader in the LUNG NET Task Force of the European Neuroendocrine Tumor Society.

I am a Medical Consultant in the Private Sector of Hospitals in Athens Greece such as Hygeia and Mitera Hospital (I am also planning to submit in IASO Hospital).

I am a Medical Consultant delivering lectures with educational content for several Pharmaceutical Companies such as Ipsen, ASTRAZENECA, MERCK, BMS, GENESIS and MSD.

Qualifications

Certificate of Completion of Specialist Training in Medical Oncology, Athens, Greece, May 2001

PhD in Tumour Immunotherapies

Imperial College School of Medicine, London University, London, UK, Jun 1998

Thesis title: Development of a novel bispecific antibody for tumour targeting. Supervisor: Professor Gordon Stamp

Medical Degree

'La Sapienza' University of Rome, Rome, Italy, Sept 1985 – Jun 1991

Good Clinical Practice Certification

Advanced Life Support European Diploma

Current Appointment

Consultant in Medical Oncology, Oct 2012 – to date

Head of Haematology-Oncology Unit.

Fourth Department of Internal Medicine, Oncology Unit, "Attikon" University General Hospital, Athens, Greece where 5,000 patients receive consultation and 2,000 patients are treated every year

(Director: Professor Sotirios Tsiodras)

- Manage the provision of the oncology consultant service during all phases of assessment and treatment (including chemotherapy) both for inpatients and outpatients
- Provide and co-ordinate the clinical oncology management of patients with cancer to ensure best practice is maintained and the best possible care is given to patients, working closely with a multi-professional team
- Provide assessments to other departments of the hospital including medical and surgical clinics, as well as other hospitals in Athens
- Work with other Consultant Oncologists and other related disciplines such as internal medicine, radiology, radiotherapy and surgical oncology to undertake daily ward rounds; actively engaged in the management of oncology patients, including advising the clinical teams
- Sit on the oncology boards of the hospital and represent the hospital in regional meetings

- Set up the department's outpatient clinic offering assessment, diagnosis and treatment of simple and complex conditions; responsible for the smooth running of the clinic three times per week; (the clinic accepts referrals from other health professionals and self-referrals and provides 2,500 consultations on average per year)
- Participate in the hospital's shift programme with four to eight shifts per month
- Compiled clinical protocols for the treatment of colorectal cancer, breast cancer and neuroendocrine tumours and introduced them to the unit
- Deliver bed-side teaching to 4th year medical students (instructor) involving clinical examination and diagnostics, imaging and laboratory;
- Present interesting cases under treatment in the weekly medical meetings (grand rounds) of the hospital's oncology clinic
- Lead the journal club and present cases from international literature to medical students and other doctors and health professionals
- Participated as principal investigator at the nationwide clinical research programme on genetic counselling of cancer patients funded by European
- Participate as an expert in the evaluation of EU funded programs
- Principal Investigator in Phase I-IV clinical studies in breast cancer funded by Iqvia, Roche, Covance, AbbVie ecc
- Supervisor of postgraduate and postdoctoral scientists in translational research protocols and psychosocial studies mainly in the field of breast and colorectal cancer
- As principal investigator, led the research for nationwide phase II study protocol entitled "Multicenter Phase II study to evaluate the efficacy and safety of everolimus as first-line therapy in newly diagnosed patients with advanced neuroendocrine gastrointestinal tumours (ClinicalTrials.gov Identifier:NCT01648465, published)
 - Investigation of angiogenic and miRNA profile in patients with colorectal cancer
 - Nationwide record of Neuroendocrine Tumour Protocol: good, moderate and poor differentiation (for Ipsen)
- Draft and present phase II-III protocols to the Hellenic Cooperative Oncology Group and manage a team of five clinical protocol assistants
- Principal investigator of phase III and IV clinical studies for Celgene, Roche, AstraZeneca, Merck, MSD, Servier, IQVIA, ABBVIE, EXCELIA, BAYER, Nordic Pharma ecc
- Principal investigator for the Sarcoma, Neuroendocrine, Melanoma and Rare Tumors for the Hellenic Oncology Research Group and Hellenic Sarcoma Study Group
- National Representative in European Neuroendocrine Tumors Society (Neuroendocrine Tumors Registry) for the Hellenic Society of Medical Oncology
- Centre of Excellence in Neuroendocrine Tumors (ENETS accredited) since March 2017

President of the Hellenic Society of Psychoneuroimmunology in Cancer

A newly formed society dedicated to the study of the psychological, neurological and immunological pathways involved in cancer development. It is a multidisciplinary society actively involved in clinical and laboratory research investigating these pathways.

Past member of the Advisory Board of the European Neuroendocrine Tumour Society (ENETs)
<https://www.enets.org/advisory-board.html>

Member of the Scientific Committee of Hellenic Cooperative Oncology Group (HECOG, www.hecog.gr)
 The Group is active in clinical trials and translational research in all tumors.

Past appointments

Consultant in Medical Oncology, Oncology Unit, Second Department of Internal Medicine Attikon University General Hospital of Athens, Oct 2003 – September 2012

(Director Professor Theophanis Economopoulos)

Part of a team of medical oncologists. Responsible for the treatment of cancer patients with different tumor types. Coordinate the teaching of medical students and medical doctors in training. Reviewing and applying national guidelines for the treatment of cancer. Participating in research protocols for the Hellenic Cooperative Oncology Group and the Hellenic Society of Medical Oncology. Participating in industry-sponsored Clinical Studies

Consultant in Medical Oncology, Sept 2000 – Jan 2002

Clatterbridge Centre for Oncology, Wirral, UK

(Director: Assoc. Professor. Peter Clark)

Responsible for running weekly outpatient satellite clinics at three regional hospitals (Chester, Walton, Warrington Hospitals, Aintree, Liverpool) including a mobile chemotherapy unit. In addition, worked closely with radiation oncologists to treat patients undergoing combined chemotherapy and radiation with tumours of the central nervous system, head and neck, lung, breast, colorectal, cervical and uterine sarcomas

Summary of skills and experience

International collaboration in Multidisciplinary Group

I am an active member of the European Neuroendocrine Tumor Society (ENETs) I am the National Representative and the Principal Investigator for the ENETs' Neuroendocrine Tumor Registry in Greece.
 The study is supervised by the Hellenic Society of Medical Oncology (HESMO).

Medical Oncology

- Gained extensive experience in evaluating different types of oncological cases and offering appropriate treatment across the spectrum of solid tumours (lung, breast, gastrointestinal, ovarian, urinary tract, prostate, skin)
More specifically:
- Responsible for the assessment and treatment of a range of solid tumours such as lung, breast, gastrointestinal, urinary and ovary
- Set up, organised and currently lead a multidisciplinary team at a busy outpatient clinic offering assessment, diagnosis and treatment of simple and complex conditions three times per week. The clinic accepts referrals from other health professionals and self-referrals and provides 2,500 consultations on average per year
- Evaluated different types of oncologic cases of patients at three regional hospitals (once weekly from Chester, Walton, Warrington Hospitals, Aintree Liverpool) in which they operated external oncology clinics with a mobile chemotherapy unit
- Extensive experience in tumour staging, including sarcomas, upper respiratory, breast, gastrointestinal and gynaecological tumours

Patient care

- Place particular emphasis and attention on the psychological profiling and support of the patient and carers. Teaching carried out to nurses, doctors and students at any level by bedside training and role playing.
- Quality clinical studies on the psychological profile and psychosocial support of cancer patients during adjuvant and palliative cancer therapies

Cancer treatment

- Experienced in implementing/administering different types of cancer treatments including biological modifiers, hormone therapy, chemotherapy (drug dissolution and administration), evaluation of therapeutic response and addressing toxicity and complications
- Confident in treating acute complications of common tumours, such as septic shock, cord compression, superior vena cava syndrome, cardiac tamponade, thrombocytopenia and paraneoplastic syndrome
- Participate in multidisciplinary meetings including experts in surgery, anatomy, haematology, palliative care and radiotherapy with the aim of identifying the most effective treatment for each case

Oncology – Haematology

- Gained thorough experience of the treatment of patients with haematological malignancies including multiple myeloma, lymphomas, leukemias
- Specialized in myelodysplastic syndrome and thrombotic thrombocytopenic purpura treatment

Oncology – Radiology

- Worked closely with radiotherapists and deepened knowledge of the principles of radiotherapy including conformal, IMRT and cyberknife and simple, radical and palliative: its clinical indications, the dose rate and fractionation, co-administration of radiation and chemotherapy and effectiveness, limitations and toxicity of radiation (early and late)
- Trained in combined treatment of patients suffering from tumours of the central nervous system, head and neck, lung, breast, colorectal, cervical and uterine sarcomas
- Took part in a thorough training programme involving both lectures and seminars in new research developments, such as gene therapy and PET scan
- Trained in radiotherapy in breast and prostate cancer as part of a 12-day course at Hammersmith and Charing Cross Hospitals

Breast Cancer Diagnosis and Treatment

- Gained extensive experience of conducting clinical breast examinations, diagnosing breast cancer, conducting breast biopsy by fine needle aspiration (FNA and FNB) under ultrasound guidance, reading and interpreting imaging tests (ultrasound, mammography)

Palliative Care

- Gained training and experience in palliative care (analgesia and other forms of symptomatic treatment) and the counselling of cancer patients and their families

Primary Care Input

- Assessed, diagnosed and treated patients in a primary care setting, including liaising with specialists and providing pre-hospital emergency care
- Solely responsible for the ongoing prescription of medication and treatments
- Worked resident night shifts: assessed and treated patients at the accident and emergency department/or patients with acute complaints

Managerial Experience

As Consultant in Medical Oncology, at the 4th and 2nd Department of Internal Medicine- Oncology Unit, "Attikon" University General Hospital, Athens, Greece

- Oversaw the establishment, organisation and coordination of the newly formed medical oncology clinic including the chemotherapy and outpatient clinic
- Compiled clinical protocols for the treatment of colorectal cancer, breast cancer and neuroendocrine tumours and introduced these to the unit
- As principal investigator led the research for nationwide phase II study protocol entitled "Multicenter Phase II study of a treatment arm to evaluate the efficacy and safety of everolimus as first-line therapy in newly diagnosed patients with advanced neuroendocrine gastrointestinal tumours: (ClinicalTrials.gov Identifier:NCT01648465)
- Member of the steering committee of neuroendocrine diseases (Hellenic Society of Medical Oncology)

As Registrar at Clatterbridge Centre for Oncology, Wirral, UK:

- Led and managed the medical oncology departments, including clinical audit and governance
- Attended internal training: Managing Employee Relations, Bullying and Harassment, Clinical Law, Ethics and Risks Clinical Supervision, Appraisal, Assessment and Accountability

Participation in Peer Reviewed Journals

I am Assistant Editor in the Journal of Endocrinological Investigations since 2023.

I am in the Editorial Board of MDPI Journals and a regular manuscript reviewer for journals included in the portfolio of SPRINGER and WILEY publishers.

Continuous Education - Attachment

MBA in Health Management 2024-today, National and Kapodistrian University of Athens Greece. I am a part time student in this MBA

Postgraduate Course in Neuroendocrine Tumors. European Neuroendocrine Tumors Society 2004-2024. I am going to sit the exams for UEMS specialization title in Neuroendocrine Tumors.

Master Class in Neuroendocrine Tumors Athens Greece 2014- 2024 (each year)

Clinical Attachment: Professor Robert Leonard and Professor Jonathan Waxman in Breast and Prostate Cancer Clinic, 80 hours, Imperial College - School of Medicine, Hammersmith and Charing Cross Hospitals, 18 – 29 Feb 2008, London, UK

Advanced Course on Diagnosis and Treatment of Neuroendocrine Tumours, Uppsala, Sweden, Uppsala University, Neuroendocrine Clinic, 12-13 Sept 2006

Participated in NHS Courses:

- Leading and Managing
- Clinical Audit/Governance
- Bullying Harassment
- Clinical Law and Ethics
- Performance Management

Research

Research stems from clinical work which encompasses the entire spectrum of Medical Oncology. As a member of the Greek Cooperative Oncology Group (HECOG), participated in many prospective and randomized clinical trials on palliative support and treatment of patients with malignant tumours.

I established a clinical trial UNIT at IVth Department of Internal Medicine, Hematology Oncology Unit, Attikon University Hospital, Athens, Greece

Current research projects:

Leading International and National Phase I-IV Clinical Studies

I am the Principal Investigator (PI) in more than 25, Phase I-IV, International Clinical Studies in Breast, Lung, Colorectal and Urogenital cancer (Data Available on Demand).

I am the PI in more than 50 National Clinical Studies.

Participation in multicenter studies (Focus on NET)

I participate in several national and international clinical trials in the field of solid malignancies (data available on demand). For example:

Greek database of neuroendocrine tumours: a Greek study registering patients aiming to monitor neuroendocrine tumours (study registration G NET).

- National research log (Registry, Abstracts and full paper published)).
- ENET's Database Registry
- Scientific Project Leader and Principal investigator in ENETS Lung NET Task Force
- ENETs Centre of excellence. EKPA LAIKO and Hematology Oncology Unit, Fourth Department of Internal Medicine, Attikon University General Hospital (Leader: Prof. G. Kaltsas).

Multicenter Phase II study of a treatment arm to evaluate the efficacy and safety of everolimus as first-line therapy in newly diagnosed patients with advanced neuroendocrine gastrointestinal tumours.

- Nationwide phase IV clinical study of Hellenic Cooperative Oncology Group (HECOG)
- Principal Investigator
- Sponsor Company: Novartis.
- Institution Oncology Unit, Fourth Department of Internal Medicine, Attikon University General Hospital of Athens
- Started on 2015 (completed in June 2016).
- Analysis completed, data published

Postgraduate Studies: PhD

PhD in Tumour Immunotherapies, Sept 1994 – June 1998

- Conducted research and developed a monoclonal antibody with dual specificity to MUC1. This is a tumour antigen expressed by adenocarcinomas such as breast cancer, and the CD3 surface antigen of T-lymphocytes
- Conducted animal model study involving the harvesting of mouse spleens and *in vitro* activation of T cells against MUC1 expressing MCF-7 breast cancer cells.
- Reviewed the most important immunotherapeutic approaches, such as cancer vaccines, and demonstrated that monoclonal antibodies can successfully redirect cytotoxic T lymphocytes against tumour cells expressing tumour antigens on their cell membrane. The tumour target antigen was the MUC1 mucin, a glycosylated protein, which is expressed on the cell membrane of many adenocarcinomas (breast, ovarian and pancreatic)
- Since then four new monoclonal antibodies, the anti-c-erbB-2 (Herceptin), the anti-CD20 (Mabthera), the anti VEGF (Bevacizumab, Avastin) and the anti-c-erbB-1 (Cetuximab), have been introduced in clinical practice for the treatment of breast cancer, non-Hodgkin's lymphoma and colon cancer
- The monoclonal antibody against MUC1, which I used in my doctoral thesis, is in a phase III study by Roche, as a second-line therapy in patients with ovarian adenocarcinoma.

**MD Thesis in connective and adipose dystrophy of the breast tissue, Medical School University of Rome
Sept 1990 – June 1991**

Research Grants

EOPE (2020-2021): Angiogenesis and microRNAs in stage IV colorectal cancer. Study is ongoing

Ministry of Health (2008-2010): Angiogenesis in colorectal cancer: 12,000€

Ministry of Health, Directorate for Training and Research: Does the genetic background affect the therapeutic outcome? Analysis of the angiogenesis pathway by PCR and immunohistochemistry in patients with metastatic adenocarcinoma of the colon, who received the first-line treatment with bevacizumab. A translational research correlate molecular profile and response to therapy.

Study completed and published

University of Athens (ELKE): Regulatory T cells in the serum and tumour tissue of patients with solid tumours: 6,000€

Scientific Project Leader: A. Koumarianou

Supervisors: Professors T. Economopoulos and N. Tountas.

Funding: University of Athens (Special Research Account)

Study completed and published

Teaching Experience

Training of medical students, foundation doctors and registrars:

As Consultant in Medical Oncology at Attikon University General Hospital

Since 2003 I am an instructor of 4th and 6th year medical students in bedside courses, clinical examination and diagnostics including imaging and laboratory; presentation of interesting cases under treatment at the oncology clinic of the hospital in weekly medical meetings (grand rounds); led the journal club studying and discussing cases from international literature. Instructor of the 6th year medical students with lectures on Tumour Markers, Paraneoplastic Syndromes and Oncological Emergencies.

As Consultant in Medical Oncology at Clatterbridge Centre for Oncology: taught medical students and foundation doctors

As Registrar at Evangelismos Hospital:

Trained undergraduate and postgraduate medical students and foundation doctors on different biopsy techniques and cancer immunology and immunotherapy; training was delivered through lectures (using PowerPoint presentations) and a series of clinical courses

As Registrar in Medical-Oncology, Hammersmith Centre of Imperial College and PhD Student:

Participated in bedside teaching of younger junior doctors and medical students on cancer, immunology and immunotherapy

Training of nurses:

As Consultant at Attikon University General Hospital: trained students undertaking a Masters in nursing oncology including one-to-one practice in the outpatient clinic

Training of post-graduate medical students & Research Supervision

Faculty of Medicine, National and Kapodistrian University of Athens, Sept 2008 – to date

Designed and delivered an eight-hour postgraduate course on stress-induced pathology entitled: 'Stress management and health promotion' with an ongoing satisfaction rate of 98%.

I am supervising the Master Thesis of one student each year.

I supervise three PhD students in the field of colorectal cancer (2) and neuroendocrine tumours (1)

Invited lectures

I am an invited speaker in several National Meetings in the field of Oncology.

I deliver presentations in English language as an invited speaker in International Conferences such as for NANETS, ENETS, ENEA, ECIO and INCA. (data available on demand).

Public Health Training

• **Lectures in Public**

• "Development of Public Health - Prevention, Information and Treatment of Cancer" with specialization in "Interdisciplinary approach to the prevention and treatment of cancer", under the Operational Programme "Health and Welfare 2000-2006" Axis 1 : "Health, Measure 4:" Development of Public Health". (Third Community Support Framework 2000-2006).

• Organization: Volunteer Group against Cancer "Embrace" with co-financing of the European Social Fund (75%) and National Resources (25%). Participation with 10 hours of instruction from 20/3/2007 to 26/6/2007

Audits

• Participated in an audit investigating the implementation of new guidelines on the medical treatment of patients treated by surgery for early-stage Gastrointestinal Stromal Tumours. The results of this work were presented at the Mediterranean Oncology Forum Conference in Istanbul, Turkey, in 2011. A full paper was published in peer reviewed journal.

Publications in Peer Reviewed Journals

Paper published but not showing yet on PUBMED: Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study. E. Fountzilas, S. Karageorgopoulou, G. Karakatsoulis, D. Tryfonopoulos, K. Papazisis, A. Koutras, A. Koumariannou, G. Zafeiri, E. Bizioti, A. Nikolaidi, I. Boukovinas, E. Vrana, D. Mauri, E. Aravantinou-Fatorou, E. Razis, E. Vorrias, Z. Saridaki, D. Bafaloukos, A. Christopoulou, A. Boutis, N. Tsoukalas, S. Stamatopoulou, N. Spathas, M. Theochari, F. Zagouri, A. Psyri, G. Fountzilas, E. Lalla. SMO Real World Data and Digital Oncology, Volume 7, 2025, 100095, ISSN 2949-8201, <https://doi.org/10.1016/j.esmorw.2024.100095>.

1: Prasad V, Koumariannou A, Denecke T, Sundin A, Deroose CM, Pavel M, Christ E, Lamarca A, Caplin M, Castaño JP, Dromain C, Falconi M, Grozinsky-Glasberg S, Hofland J, Knigge UP, Kos-Kudla B, Krishna BA, Reed NS, Scarpa A, Srirajaskanthan R, Toumpanakis C, Kjaer A, Hicks RJ, Ambrosini V. Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force. J Neuroendocrinol. 2025 Feb;37(2):e13479. doi: 10.1111/jne.13479. Epub 2024 Dec 9. PMID: 39653582.

2: Pateras IS, Kostopanagiotou K, Samaras MG, Koumariannou A, Koutrouli M, Korodimos N, Kampoli K, Apolloniatou V, Manali E, Loukides S, Tomos P, Tsiodras S, Panayiotides IG. Rare cancer with primary pleural epithelioid hemangioendothelioma diagnosed by thoracoscopic biopsy achieving disease control

after 16 months: case report and literature review. *Front Pharmacol*. 2024 Nov 22;15:1482154. doi: 10.3389/fphar.2024.1482154. PMID: 39650162; PMCID: PMC11621942.

3: Nikolaidi A, Papadopoulou E, Haidopoulos D, Lontos M, Fountzilias E, Tsaousis G, Goula K, Tsolaki E, Christopoulou A, Binas I, Stamatopoulou S, Koumarianou A, Karageorgopoulou S, Goussia A, Psyri A, Papadimitriou C, Gogas H. Molecular Alterations in Paired Epithelial Ovarian Tumors in Patients Treated with Neoadjuvant Chemotherapy. *Cancers (Basel)*. 2024 Oct 24;16(21):3580. doi: 10.3390/cancers16213580. PMID: 39518021; PMCID: PMC11545381.

4: Tsoulos N, Papadopoulou E, Agiannitopoulos K, Grigoriadis D, Tsaousis GN, Bouzarelou D, Gogas H, Troupis T, Venizelos V, Fountzilias E, Theochari M, Ziogas DC, Giassas S, Koumarianou A, Christopoulou A, Busby G, Nasioulas G, Markopoulos C. Polygenic Risk Score (PRS) Combined with NGS Panel Testing Increases Accuracy in Hereditary Breast Cancer Risk Estimation. *Diagnostics (Basel)*. 2024 Aug 21;14(16):1826. doi: 10.3390/diagnostics14161826. PMID: 39202314; PMCID: PMC11353636.

5: Tsoulos N, Agiannitopoulos K, Potska K, Katseli A, Ntogka C, Pepe G, Bouzarelou D, Papathanasiou A, Grigoriadis D, Tsaousis GN, Gogas H, Troupis T, Papazisis K, Natsiopoulos I, Venizelos V, Amarantidis K, Giassas S, Papadimitriou C, Fountzilias E, Stathouloupoulou M, Koumarianou A, Xepapadakis G, Blidaru A, Zob D, Voinea O, Özdoğan M, Ergören MÇ, Hegmane A, Papadopoulou E, Nasioulas G, Markopoulos C. The Clinical and Genetic Landscape of Hereditary Cancer: Experience from a Single Clinical Diagnostic Laboratory. *Cancer Genomics Proteomics*. 2024 Sep-Oct;21(5):448-463. doi: 10.21873/cgp.20463. PMID: 39191493; PMCID: PMC11363926.

6: Kokkali S, Boukovinas I, de Bree E, Koumarianou A, Georgoulas V, Kyriazoglou A, Tsoukalas N, Memos N, Papanastassiou J, Stergioula A, Tsapakidis K, Loga K, Duran-Moreno J, Papanastasopoulos P, Vassos N, Kontogeorgakos V, Athanasiadis I, Mahaira L, Dimitriadis E, Papachristou DJ, Agrogiannis G. The Impact of Expert Pathology Review and Molecular Diagnostics on the Management of Sarcoma Patients: A Prospective Study of the Hellenic Group of Sarcomas and Rare Cancers. *Cancers (Basel)*. 2024 Jun 24;16(13):2314. doi: 10.3390/cancers16132314. PMID: 39001377; PMCID: PMC11240402.

7: Agiannitopoulos K, Katseli A, Potska K, Ntogka C, Tsaousis GN, Tsoulos N, Kampoli K, Ntavatzikos A, Papadopoulou E, Nasioulas G, Koumarianou A. Germline Co-deletion of *CDKN2A* and *CDKN2B* Genes in Pleomorphic Xanthoastrocytoma: Case Report. *In Vivo*. 2024 Jul-Aug;38(4):1671-1676. doi: 10.21873/invivo.13617. PMID: 38936911; PMCID: PMC11215628.

8: Kampoli K, Tsamis I, Sgouros D, Katsimbri P, Koumarianou A. Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapy. *Immunotherapy*. 2024;16(11):709-714. doi: 10.1080/1750743X.2024.2362107. Epub 2024 Jun 18. PMID: 38888430; PMCID: PMC11421299.

9: Koumarianou A, Filosso PL, Bodei L, Castano JP, Fernandez-Cuesta L, Deroose CM, Foll M, Dromain C, Reed NS, Caplin M, Capdevila J, Falkerby J, Faggiano A, Frilling A, Grande E, Hicks RJ, Kasajima A, Kos-Kudla B, Krishna BA, Lim E, Rinke A, Singh S, Thirlwell C, Volante M, Walter T. Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force. *J Neuroendocrinol*. 2024 Aug;36(8):e13412. doi: 10.1111/jne.13412. Epub 2024 May 16. PMID: 38754956.

10: Angelousi A, Tzoulis P, Tsoli M, Chatzellis E, Koumarianou A, Kaltsas G. Immunotherapy for endocrine tumours: a clinician's perspective. *Endocr Relat Cancer*. 2024 Feb 12;31(4):e230296. doi: 10.1530/ERC-23-0296. PMID: 38235757.

11: Ziogas DC, Papadopoulou E, Gogas H, Sakellariou S, Felekouras E, Theocharopoulos C, Stefanou DT, Theochari M, Boukovinas I, Matthaios D, Koumarianou A, Zairi E, Lontos M, Koutsoukos K, Metaxa-Mariatou V, Kapetsis G, Meintani A, Tsaousis GN, Nasioulas G. Digging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction. *Cancers (Basel)*. 2023 Dec 19;16(1):2. doi: 10.3390/cancers16010002. PMID: 38201431; PMCID: PMC10778112.

12: Dimitrakopoulos FI, Goussia A, Koliou GA, Dadouli K, Batistatou A, Kourea HP, Bobos M, Arapantoni-Dadioti P, Tzaida O, Koletsa T, Chrisafi S, Sotiropoulou M, Papoudou-Bai A, Nicolaou I, Charchanti A, Mauri D, Aravantinos G, Binas I,

Res E, Psyrris A, Pectasides D, Bafaloukos D, Koumarianou A, Bompolaki I, Rigakos G, Karanikiotis C, Koutras A, Zagouri F, Gogas H, Fountzilas G. Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes. *Breast*. 2024 Feb;73:103668. doi: 10.1016/j.breast.2023.103668. Epub 2023 Dec 25. PMID: 38176305; PMCID: PMC10791571.

13: Ambrosini V, Caplin M, Castaño JP, Christ E, Denecke T, Deroose CM, Dromain C, Falconi M, Grozinsky-Glasberg S, Hicks RJ, Hofland J, Kjaer A, Knigge UP, Kos-Kudla B, Koumarianou A, Krishna B, Lamarca A, Pavel M, Reed NS, Scarpa A, Srirajaskanthan R, Sundin A, Toumpanakis C, Prasad V. Use and perceived utility of [¹⁸F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022. *J Neuroendocrinol*. 2024 Jan;36(1):e13359. doi: 10.1111/jne.13359. Epub 2023 Dec 14. PMID: 38097193.

14: Fountzilas E, Papadopoulou K, Chatzikonstantinou T, Karakatsoulis G, Constantoulakis P, Tsantikidi A, Tsaousis G, Karageorgopoulou S, Koumarianou A, Mauri D, Ntavatzikos A, Saridaki Z, Petrakis G, Fostira F, Fountzilas G, Lontos M. Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer. *Cancers (Basel)*. 2023 Nov 22;15(23):5525. doi: 10.3390/cancers15235525. PMID: 38067228; PMCID: PMC10705222.

15: Vassilakopoulos TP, Piperidou A, Mellios Z, Verigou E, Katodritou E, Kalpadakis C, Papageorgiou SG, Chatzidimitriou C, Prassopoulos V, Siakantaris MP, Giatra H, Karantanis D, Papathanasiou N, Ligdi L, Kopsaftopoulou A, Leonidopoulou T, Xanthopoulos V, Karakatsanis S, Vrakidou E, Chatziioannou S, Drougkas D, Hatzimichael E, Gainaru G, Palassopoulou M, Tsirogianni M, Kotsopoulou M, Tsourouflis G, Skoura E, Mainta C, Terpos E, Poziopoulos C, Triantafyllou T, Zikos P, Koumarianou A, Liapi D, Pappa V, Verrou E, Tsigotis P, Labropoulou V, Papadaki H, Datseris I, Symeonidis A, Bouzani M, Bakiri M, Karmiris T, Angelopoulou MK, Rondogianni P. PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated? *Hemasphere*. 2023 Nov 7;7(11):e965. doi: 10.1097/HS9.0000000000000965. PMID: 38027423; PMCID: PMC10631617.

16: Agiannitopoulos K, Potska K, Katseli A, Ntogka C, Tsaousis GN, Pepe G, Bouzarelou D, Tsoulos N, Papathanasiou A, Ziogas D, Venizelos V, Markopoulos C, Iosifidou R, Karageorgopoulou S, Giassas S, Natsiopoulos I, Papazisis K, Vasilaki-Antonatou M, Psyrris A, Koumarianou A, Matthaios D, Zairi E, Blidaru A, Banu E, Jinga DC, Laçin Ş, Özdoğan M, Papadopoulou E, Nasioulas G. Only 32.3% of Breast Cancer Families with Pathogenic Variants in Cancer Genes Utilized Cascade Genetic Testing. *Cancers (Basel)*. 2023 Oct 30;15(21):5218. doi: 10.3390/cancers15215218. PMID: 37958392; PMCID: PMC10649031.

17: Kos-Kudla B, Castaño JP, Denecke T, Grande E, Kjaer A, Koumarianou A, de Mestier L, Partelli S, Perren A, Stättner S, Valle JW, Fazio N. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. *J Neuroendocrinol*. 2023 Dec;35(12):e13343. doi: 10.1111/jne.13343. Epub 2023 Oct 25. PMID: 37877341.

18: Koinis F, Zafeiriou Z, Messaritakis I, Katsaounis P, Koumarianou A, Kontopodis E, Chantzara E, Aidarinis C, Lazarou A, Christodoulouopoulos G, Emmanouilides C, Hatzidaki D, Kallergi G, Georgoulas V, Kotsakis A. Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study. *Cancers (Basel)*. 2023 Sep 11;15(18):4511. doi: 10.3390/cancers15184511. PMID: 37760481; PMCID: PMC10527446.

19: Machairoudia G, Kazantzis D, Chatziralli I, Kampoli K, Ntavatzikos A, Theodossiadi P, Koumarianou A. Prevalence and risk factors of dry eye disease in patients treated with aromatase inhibitors for breast cancer. *Clin Exp Optom*. 2024 May;107(4):415-419. doi: 10.1080/08164622.2023.2239247. Epub 2023 Sep 12. PMID: 37699786.

20: Agiannitopoulos K, Pepe G, Tsaousis GN, Potska K, Bouzarelou D, Katseli A, Ntogka C, Meintani A, Tsoulos N, Giassas S, Venizelos V, Markopoulos C, Iosifidou R, Karageorgopoulou S, Christodoulou C, Natsiopoulos I, Papazisis K,

Vasilaki-Antonatou M, Kabletsas E, Psyrris A, Ziogas D, Lalla E, Koumariou A, Anastasakou K, Papadimitriou C, Ozmen V, Tansan S, Kaban K, Ozatli T, Eniu DT, Chiorean A, Blidaru A, Rinsma M, Papadopoulou E, Nasioulas G. Copy Number Variations (CNVs) Account for 10.8% of Pathogenic Variants in Patients Referred for Hereditary Cancer Testing. *Cancer Genomics Proteomics*. 2023 Sep-Oct;20(5):448-455. doi: 10.21873/cgp.20396. PMID: 37643779; PMCID: PMC10464942.

21: Rinke A, Ambrosini V, Dromain C, Garcia-Carbonero R, Haji A, Koumariou A, van Dijkum EN, O'Toole D, Rindi G, Scoazec JY, Ramage J. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours. *J Neuroendocrinol*. 2023 Jun;35(6):e13309. doi: 10.1111/jne.13309. Epub 2023 Jun 22. PMID: 37345509.

22: Tsoli M, Koumariou A, Angelousi A, Kaltsas G. Established and novel circulating neuroendocrine tumor biomarkers for diagnostic, predictive and prognostic use. *Best Pract Res Clin Endocrinol Metab*. 2023 Sep;37(5):101785. doi: 10.1016/j.beem.2023.101785. Epub 2023 Jun 5. PMID: 37336711.

23: Linardou H, Lampaki S, Koliou GA, Vozikis A, Boutis A, Nikolaidi A, Kontogiorgos I, Papakotoulas P, Christopoulou A, Spyrtatos D, Bafaloukos D, Psyrris A, Grivas A, Koumariou A, Tsiakitzis K, Mauri D, Rigakos G, Aravantinos G, Papantoniou P, Oikonomopoulos G, Fountzilas E, Koufaki MI, Kaparelou M, Liolis E, Mountzios G, Kosmidis P, Fountzilas G, Samantas E. Real-world Data and Economic Evaluation of Nivolumab in Previously Treated Non-small Cell Lung Cancer Greek Patients. *Anticancer Res*. 2023 Jun;43(6):2799-2812. doi: 10.21873/anticancer.16449. PMID: 37247889.

24: Koumariou A, Ntavatzikos A, Symeonidis D, Vallilas C, Giannakakou M, Papaxoinis G, Xynogalos S, Boukovinas I, Demiri S, Kampoli K, Oikonomopoulos G, Samantas E, Res E, Androulakis N, Vourli G, Souglakos I, Karamouzis M. RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer. *Biomedicines*. 2023 Apr 24;11(5):1267. doi: 10.3390/biomedicines11051267. PMID: 37238938; PMCID: PMC10215810.

25: Mountzios G, Koumariou A, Linardou H, Boutis A, Mavroudis D, Samantas E, Korantzis I, Athanasiadis E, Fergadis EG, Lampaki S, Georgoulas V, Baka S, Karamouzis MV, Boukovinas I, Andreadis C, Rapti A, Koulouris N, Pentheroudakis G, Froudarakis ME, Somarakis A, Anastasopoulou E, Karadimou A, Papageorgiou F, Paparepa Z, Nikolaou A, Papista C, Syrigos KN. Clinical Outcomes Beyond 1L <i>EGFR</i>-TKI Progression in mNSCLC: Final Results of the Real-World Study 'LUNGFUL'. *Anticancer Res*. 2023 May;43(5):2243-2258. doi: 10.21873/anticancer.16388. PMID: 37097667.

26: Fazio N, Gervaso L, Halfdanarson TR, Sonbol M, Eiring RA, Pusceddu S, Prinzi N, Lombardi Stocchetti B, Grozinsky-Glasberg S, Gross DJ, Walter T, Robelin P, Lombard-Bohas C, Frassoni S, Bagnardi V, Antonuzzo L, Sparano C, Massironi S, Gelsomino F, Bongiovanni A, Ranallo N, Tafuto S, Rossi M, Cives M, Rasul Kakil I, Hamid H, Chirco A, Squadroni M, La Salvia A, Hernando J, Hofland J, Koumariou A, Boselli S, Tamayo D, Mazzon C, Rubino M, Spada F. COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study. *Endocr Relat Cancer*. 2023 Apr 26;30(6):e220395. doi: 10.1530/ERC-22-0395. PMID: 36930250.

27: Mountzios G, Planchard D, Metro G, Tsiouda D, Prelaj A, Lampaki S, Shalata W, Riudavets M, Christopoulos P, Girard N, Albarrán-Artahona V, Garcia Campelo R, Samitas K, Banna GL, Boukovinas I, Agbarya A, Koumariou A, Perdikouri EI, Kosmidis P, Linardou H, Mauri D, Mavroudis D, Athanasiadis I, Kalofonos H, Xenidis N, Korantzis I, Ardavanis A, Rallis G, Bottiglieri A, Efthymiadis K, Oikonomopoulos G, Kokkalis A, Saloustros E, Tsoukalas N, Bartzis D, Economopoulou P, Psyrris A, Reck M, Lo Russo G. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry. *JTO Clin Res Rep*. 2022 Nov 20;4(1):100433. doi: 10.1016/j.jtocrr.2022.100433. PMID: 36793384; PMCID: PMC9923191.

28: Tomos I, Kapetanakis EI, Dimakopoulou K, Raptakis T, Kampoli K, Karakatsani A, Koumariou A, Papiris S, Tomos P. The Impact of COVID-19 Pandemic on Surgical Treatment of Resectable Non-Small Cell Lung Cancer in Greece. *Life (Basel)*. 2023 Jan 12;13(1):218. doi: 10.3390/life13010218. PMID: 36676167; PMCID: PMC9864579.

29: Angelousi A, Koumariou A, Chatzellis E, Kaltsas G. Resistance of

neuroendocrine tumours to somatostatin analogs. *Expert Rev Endocrinol Metab.* 2023 Jan;18(1):33-52. doi: 10.1080/17446651.2023.2166488. Epub 2023 Jan 18. PMID: 36651768.

30: Apeessos A, Agiannitopoulos K, Pepe G, Tsaousis GN, Pitta P, Bili C, Florentin L, Saloustros E, Kampletsas E, Tryfonopoulos D, Tsoukalas N, Bournakis E, Zagouri F, Kotsakis A, Koumarianou A, Korantzis I, Boukovinas I, Lypas G, Fountzilas G, Michalaki V, Xynogalos S, Linardou H, Papadopoulou E, Nasioulas G, Georgoulas V. Genetic Predisposition to Male Breast Cancer: A Case Series. *Anticancer Res.* 2022 Dec;42(12):5795-5801. doi: 10.21873/anticancer.16086. PMID: 36456130.

31: Spathas N, Goussia AC, Koliou GA, Gogas H, Zagouri F, Batistatou A, Charchanti AV, Papoudou-Bai A, Bobos M, Chrisafi S, Chatzopoulos K, Kostopoulos I, Koletsa T, Arapantoni P, Pectasides D, Galani E, Koutras A, Zarkavelis G, Saloustros E, Bafaloukos D, Karanikiotis C, Bompolaki I, Aravantinos G, Psyrri A, Razis E, Koumarianou A, Res E, Linardou H, Fountzilas G. Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy-A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study. *Cancers (Basel).* 2022 Nov 16;14(22):5635. doi: 10.3390/cancers14225635. PMID: 36428728; PMCID: PMC9688913.

32: Carlsson G, Koumarianou A, Guren TK, Haux J, Katsaounis P, Kentepozidis N, Pfeiffer P, Brændengen M, Mavroudis D, Taflin H, Skintemo L, Tell R, Papadimitriou C. A phase I/II study of arfolitoxorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer. *ESMO Open.* 2022 Oct;7(5):100589. doi: 10.1016/j.esmoop.2022.100589. Epub 2022 Sep 29. PMID: 36183444; PMCID: PMC9588906.

33: Papadopoulou K, Koliou GA, Tsimiliotis D, Kotoula V, Foukas P, Goussia A, Tsiatas M, Visvikis A, Chatzopoulos K, Nifora M, Charchanti A, Koumarianou A, Christodoulou C, Pectasides D, Psyrri A, Fostira F, Fountzilas G, Samantas E. Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens. *Urol Oncol.* 2022 Dec;40(12):538.e15-538.e24. doi: 10.1016/j.urolonc.2022.07.007. Epub 2022 Aug 28. PMID: 36041976.

34: Koulouridi A, Karagianni M, Messaritakis I, Sfakianaki M, Voutsina A, Trypaki M, Bachlitzanaki M, Koustas E, Karamouzis MV, Ntavatzikos A, Koumarianou A, Androulakis N, Mavroudis D, Tzardi M, Souglakos J. Prognostic Value of KRAS Mutations in Colorectal Cancer Patients. *Cancers (Basel).* 2022 Jul 7;14(14):3320. doi: 10.3390/cancers14143320. PMID: 35884381; PMCID: PMC9313302.

35: Koumarianou A, Daskalakis K, Tsoli M, Kaltsas G, Pavel M. Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome. *J Neuroendocrinol.* 2022 Jul;34(7):e13174. doi: 10.1111/jne.13174. Epub 2022 Jul 6. Erratum in: *J Neuroendocrinol.* 2024 Jan;36(1):e13361. doi: 10.1111/jne.13361. PMID: 35794780.

36: Zagouri F, Koliou GA, Dimitrakopoulos F, Papadimitriou C, Binas I, Koutras A, Papakostas P, Markopoulos C, Venizelos V, Xepapadakis G, Andrikopoulou A, Karanikiotis C, Psyrri A, Bafaloukos D, Kosmidis P, Aravantinos G, Res E, Mauri D, Koumarianou A, Petraki K, Tsipoura A, Pectasides D, Gogas H, Fountzilas G. Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial. *Br J Cancer.* 2022 Sep;127(4):695-703. doi: 10.1038/s41416-022-01846-y. Epub 2022 May 24. PMID: 35610366; PMCID: PMC9381581.

37: Kallergi G, Kontopodis E, Ntzifa A, Jordana-Ariza N, Karachaliou N, Pantazaka E, Charalambous HA, Psyrri A, Tsaroucha E, Boukovinas I, Koumarianou A, Hatzidaki D, Lianidou E, Georgoulas V, Rosell R, Kotsakis A. Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy. *Cancers (Basel).* 2022 Mar 19;14(6):1574. doi: 10.3390/cancers14061574. PMID: 35326725; PMCID: PMC8946716.

38: Borbath I, Pape UF, Deprez PH, Bartsch DK, Caplin M, Falconi M, Garcia-Carbonero R, Grozinsky-Glasberg S, Jensen RT, Arnold R, Ruzsniowski P, Toumpanakis C, Valle JW, O Toole D; Members of the Advisory Board of the European Neuroendocrine Tumor Society (ENETS). ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. *J Neuroendocrinol.* 2022

Mar;34(3):e13105. doi: 10.1111/jne.13105. Epub 2022 Mar 1. PMID: 35233848.

39: Wedin M, Tsoli M, Wallin G, Janson ET, Koumarianou A, Kaltsas G, Daskalakis K. Heterogeneity of Small Intestinal Neuroendocrine Tumors Metastasis: Biologic Patterns of a Series with Virchow's Node Involvement. *Cancers (Basel)*. 2022 Feb 12;14(4):913. doi: 10.3390/cancers14040913. PMID: 35205660; PMCID: PMC8869999.

40: Kampoli K, Foukas PG, Ntavatzikos A, Arkadopoulos N, Koumarianou A. Interrogating the interplay of angiogenesis and immunity in metastatic colorectal cancer. *World J Methodol*. 2022 Jan 20;12(1):43-53. doi: 10.5662/wjm.v12.i1.43. PMID: 35117981; PMCID: PMC8790311.

41: Seliniotaki T, Bacopoulou F, Vlachakis D, Artemiadis A, Kampoli K, Chrousos G, Darviri C, Koumarianou A. Effects of an 8-Week Stress Management Program in Women with Breast Cancer: A Randomized Controlled Trial. *Adv Exp Med Biol*. 2021;1339:85-95. doi: 10.1007/978-3-030-78787-5_12. PMID: 35023094.

42: Seliniotaki T, Koumarianou A, Bacopoulou F, Vlachakis D, Chrousos GP, Darviri C. Event-Related Rumination Inventory: A Validation Process in the Greek Language. *Adv Exp Med Biol*. 2021;1337:149-158. doi: 10.1007/978-3-030-78771-4_17. PMID: 34972901.

43: Tsaousis GN, Papadopoulou E, Agiannitopoulos K, Pepe G, Tsoulos N, Boukovinas I, Floros T, Iosifidou R, Katopodi O, Koumarianou A, Markopoulos C, Papazisis K, Venizelos V, Kapsimalis A, Xepapadakis G, Psyrris A, Banu E, Eniu DT, Blidaru A, Stanculeanu DL, Ungureanu A, Ozmen V, Tansan S, Tekinel M, Yalcin S, Nasioulas G. Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients. *Cancer Genomics Proteomics*. 2022 Jan-Feb;19(1):60-78. doi: 10.21873/cgp.20304. PMID: 34949660; PMCID: PMC8717958.

44: Kole C, Charalampakis N, Tsakatikas S, Kouris NI, Papaxoinis G, Karamouzis MV, Koumarianou A, Schizas D. Immunotherapy for gastric cancer: a 2021 update. *Immunotherapy*. 2022 Jan;14(1):41-64. doi: 10.2217/imt-2021-0103. Epub 2021 Nov 17. PMID: 34784774.

45: Fazio N, Gervaso L, Halfdanarson TR, La Salvia A, Hofland J, Hernando J, Sonbol MB, Garcia-Carbonero R, Capdevila J, de Herder WW, Koumarianou A, Kaltsas G, Rossi M, Grozinsky-Glasberg S, Oleinikov K, Boselli S, Tamayo D, Bagnardi V, Laffi A, Rubino M, Spada F. Corrigendum to 'Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study' [*European Journal of Cancer* 154 (2021) 246-252]. *Eur J Cancer*. 2022 Jan;160:289-290. doi: 10.1016/j.ejca.2021.10.001. Epub 2021 Oct 21. Erratum for: *Eur J Cancer*. 2021 Sep;154:246-252. doi: 10.1016/j.ejca.2021.06.029. PMID: 34690038; PMCID: PMC8529581.

46: Hicks RJ, Dromain C, de Herder WW, Costa FP, Deroose CM, Frilling A, Koumarianou A, Krenning EP, Raymond E, Bodei L, Sorbye H, Welin S, Wiedenmann B, Wild D, Howe JR, Yao J, O'Toole D, Sundin A, Prasad V. ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. *J Neuroendocrinol*. 2022 Mar;34(3):e13040. doi: 10.1111/jne.13040. Epub 2021 Oct 20. PMID: 34668262; PMCID: PMC11042683.

47: Mountzios G, Lampaki S, Koliou GA, Vozikis A, Kontogiorgos I, Papantoniou P, Koufaki MI, Res E, Boutis A, Christopoulou A, Pastelli N, Grivas A, Aravantinos G, Lalla E, Oikonomopoulos G, Koumarianou A, Spyrtatos D, Bafaloukos D, Rigakos G, Papakotoulas P, Fountzilas G, Linardou H. An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece. *Lung Cancer (Auckl)*. 2021 Aug 30;12:93-102. doi: 10.2147/LCTT.S318007. PMID: 34512058; PMCID: PMC8415762.

48: Kole C, Charalampakis N, Vailas M, Tolia M, Sotiropoulou M, Tsakatikas S, Kouris NI, Tsoli M, Koumarianou A, Karamouzis MV, Schizas D. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update. *Cancer Immunol Immunother*. 2022 Apr;71(4):761-768. doi: 10.1007/s00262-021-03046-8. Epub 2021 Sep 1. PMID: 34471940; PMCID: PMC10992124.

49: Fazio N, Gervaso L, Halfdanarson TR, La Salvia A, Hofland J, Hernando J, Sonbol MB, Garcia-Carbonero R, Capdevila J, de Herder WW, Koumarianou A, Kaltsas G, Rossi M, Grozinsky-Glasberg S, Oleinikov K, Boselli S, Tamayo D, Bagnardi V,

Laffi A, Rubino M, Spada F. Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study. *Eur J Cancer*. 2021 Sep;154:246-252. doi: 10.1016/j.ejca.2021.06.029. Epub 2021 Jun 30. Erratum in: *Eur J Cancer*. 2022 Jan;160:289-290. doi: 10.1016/j.ejca.2021.10.001. PMID: 34298375; PMCID: PMC8241688.

50: Mountzios G, Koumarianou A, Bokas A, Mavroudis D, Samantas E, Fergadis EG, Linardou H, Katsaounis P, Athanasiadis E, Karamouzis MV, Pentheroudakis G, Lampaki S, Froudarakis ME, Perdikouri EA, Somarakis A, Papageorgiou F, Paparepa Z, Nikolaou A, Syrigos KN. A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in <i>EGFR</i> Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The 'LUNGFUL' Study. *Cancers (Basel)*. 2021 Jun 25;13(13):3172. doi: 10.3390/cancers13133172. PMID: 34202063; PMCID: PMC8268841.

51: Fountzilas E, Lampaki S, Koliou GA, Koumarianou A, Levva S, Vagionas A, Christopoulou A, Laloyssis A, Psyrris A, Binas I, Mountzios G, Kentepozidis N, Kotsakis A, Saloustros E, Boutis A, Nikolaidi A, Fountzilas G, Georgoulas V, Chrysanthidis M, Kotteas E, Vo H, Tsiatas M, Res E, Linardou H, Daoussis D, Bompilaki I, Andreadou A, Papaxoinis G, Spyrtatos D, Gogas H, Syrigos KN, Bafaloukos D. Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. *Cancer Immunol Immunother*. 2022 Feb;71(2):327-337. doi: 10.1007/s00262-021-02985-6. Epub 2021 Jun 23. PMID: 34164709; PMCID: PMC8783878.

52: Aktypis C, Spei ME, Yavropoulou M, Wallin G, Koumarianou A, Kaltsas G, Kassi E, Daskalakis K. Cardiovascular Toxicities Secondary to Biotherapy and Molecular Targeted Therapies in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. *Cancers (Basel)*. 2021 Apr 30;13(9):2159. doi: 10.3390/cancers13092159. PMID: 33946147; PMCID: PMC8124890.

53: Gourzoulidis G, Koulentaki M, Koumarianou A, Samadas E, Androulakis N, Xynogalos S, Papakotoulas P, Boukovinas I, Karamouzis M, Souglakos J, Chotzagianoglou V, Beletsi A, Kourlaba G. Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastroesophageal junction, among patients previously treated in Greece. *Expert Rev Pharmacoecon Outcomes Res*. 2022 Mar;22(2):259-269. doi: 10.1080/14737167.2021.1921576. Epub 2021 May 6. PMID: 33900864.

54: Koumarianou A, Kaltsas GA, Chatzellis E, Kyriakopoulos G, Kolomodi D, Alexandraki KI. Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms. *Endocrine*. 2021 Jul;73(1):232-239. doi: 10.1007/s12020-021-02639-8. Epub 2021 Feb 5. PMID: 33544352.

55: Koumarianou A, Duran-Moreno J. The Sarcoma Immune Landscape: Emerging Challenges, Prognostic Significance and Prospective Impact for Immunotherapy Approaches. *Cancers (Basel)*. 2021 Jan 20;13(3):363. doi: 10.3390/cancers13030363. PMID: 33498238; PMCID: PMC7863949.

56: Fountzilas E, Eliades A, Koliou GA, Achilleos A, Loizides C, Tsangaras K, Pectasides D, Sgouros J, Papakostas P, Rallis G, Psyrris A, Papadimitriou C, Oikonomopoulos G, Ferentinos K, Koumarianou A, Zarkavelis G, Dervenis C, Aravantinos G, Bafaloukos D, Kosmidis P, Papaxoinis G, Theochari M, Varthalitis I, Kentepozidis N, Rigakos G, Saridaki Z, Nikolaidi A, Christopoulou A, Fostira F, Samantas E, Kypri E, Ioannides M, Koumbaris G, Fountzilas G, Patsalis PC. Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. *Cancers (Basel)*. 2021 Jan 8;13(2):198. doi: 10.3390/cancers13020198. PMID: 33429865; PMCID: PMC7827324.

57: Koumarianou A, Ntavatzikos A, Vallilas C, Kampoli K, Kakoseou Z, Karamouzis MV. Survival Outcomes Following Combination of First-Line Platinum-Based Chemotherapy with S-1 in Patients with Advanced Gastric Cancer. *Cancers (Basel)*. 2020 Dec 15;12(12):3780. doi: 10.3390/cancers12123780. PMID: 33333977; PMCID: PMC7765389.

58: Koumarianou A, Kaltsas G. Surufatinib - a novel oral agent for neuroendocrine tumours. *Nat Rev Endocrinol*. 2021 Jan;17(1):9-10. doi: 10.1038/s41574-020-00439-0. PMID: 33128026.

59: Papaxoinis G, Athanasiadis A, Sgouros J, Visvikis A, Drizou M, Kontopodis E, Koumarianou A, Stojanovska S, Aravantinos G, Korantzis I, Ioannou A, Varthalitis I, Doufexis D, Nikolaou M, Lypas G, Bompolaki I, Christopoulou A, Lontos M, Tsoukalas N, Mauri D, Xenidis N, Katsaounis P, Oikonomopoulos G, Boukovinas I. Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece. *J Oncol.* 2020 Sep 19;2020:5304516. doi: 10.1155/2020/5304516. PMID: 33014051; PMCID: PMC7520678.

60: Fountzilias E, Koliou GA, Vozikis A, Rapti V, Nikolakopoulos A, Boutis A, Christopoulou A, Kontogiorgos I, Karageorgopoulou S, Lalla E, Tryfonopoulos D, Boukovinas I, Rapti C, Nikolaidi A, Karteri S, Moirogiorgou E, Binas I, Mauri D, Aravantinos G, Zagouri F, Saridaki Z, Psyrri A, Bafaloukos D, Koumarianou A, Res E, Linardou H, Mountzios G, Razis E, Fountzilias G, Koumakis G. Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group. *ESMO Open.* 2020 Aug;5(4):e000774. doi: 10.1136/esmoopen-2020-000774. PMID: 32817060; PMCID: PMC7437702.

61: Koumarianou A, Symeonidi AE, Kattamis A, Linardatou K, Chrousos GP, Darviri C. A review of psychosocial interventions targeting families of children with cancer. *Palliat Support Care.* 2021 Feb;19(1):103-118. doi: 10.1017/S1478951520000449. PMID: 32613930.

62: Kapetanakis EI, Filippiadis DK, Tomos IP, Karakatsani A, Koumarianou A, Tomos PI. The role of percutaneous interventions in the management of lung cancer patients during the Covid-19 pandemic. *J Surg Oncol.* 2020 Oct;122(5):989-991. doi: 10.1002/jso.26084. Epub 2020 Jun 25. PMID: 32588444; PMCID: PMC7361764.

63: Koumarianou A, Alexandraki KI, Wallin G, Kaltsas G, Daskalakis K. Pathogenesis and Clinical Management of Mesenteric Fibrosis in Small Intestinal Neuroendocrine Neoplasms: A Systematic Review. *J Clin Med.* 2020 Jun 8;9(6):1777. doi: 10.3390/jcm9061777. PMID: 32521677; PMCID: PMC7357094.

64: Kapetanakis EI, Tomos IP, Karakatsani A, Koumarianou A, Tomos PI. Management of surgical lung cancer patients during the COVID-19 pandemic in the financially and resource strained Greek health care system. *J Surg Oncol.* 2020 Aug;122(2):124-127. doi: 10.1002/jso.25988. Epub 2020 May 23. PMID: 32446272; PMCID: PMC7283720.

65: Koumarianou A, Makrantonakis P, Zagouri F, Papadimitriou C, Christopoulou A, Samantas E, Christodoulou C, Psyrri A, Bafaloukos D, Aravantinos G, Papakotoulas P, Baka S, Andreadis C, Alexopoulos A, Bompolaki I, Kampoli K, Liori S, Karvounis K, Ardavanis A. ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer. *Breast Cancer Res Treat.* 2020 Jul;182(1):85-96. doi: 10.1007/s10549-020-05677-4. Epub 2020 May 16. PMID: 32418045.

66: Koumarianou A, Pectasides D, Koliou GA, Dionysopoulos D, Kolomodi D, Poullos C, Skondra M, Sgouros J, Pentheroudakis G, Kaltsas G, Fountzilias G. Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study. *Biology (Basel).* 2020 Mar 9;9(3):51. doi: 10.3390/biology9030051. PMID: 32182791; PMCID: PMC7150771.

67: Duran-Moreno J, Kokkali S, Ramfidis V, Salomidou M, Digklia A, Koumarianou A, Tomos P, Koufopoulos N, Vamvakaris I, Psychogiou E, Syrigos K. Primary Sarcoma of the Lung - Prognostic Value of Clinicopathological Characteristics of 26 Cases. *Anticancer Res.* 2020 Mar;40(3):1697-1703. doi: 10.21873/anticancer.14122. PMID: 32132077.

68: Douridas GN, Fountoulakis A, Souglakos J, Gourtsoyianni S, Vini L, Levidou G, Liakakos T, Agalianos C, Dervenis C, Kalogeridi MA, Karavokyros I, Koumarianou A, Kountourakis P, Oikonomopoulos G, Economopoulou P, Sgouros J, Sgouros SN, Stamou K, Triantopoulou C, Zacharoulis D, Gouvas N, Xynos E. Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer. *Updates Surg.* 2020 Mar;72(1):1-19. doi: 10.1007/s13304-020-00723-8. Epub 2020 Feb 28. PMID: 32112342.

69: Fountzilias E, Kotoula V, Koliou GA, Giannoulatou E, Gogas H, Papadimitriou

C, Tikas I, Zhang J, Papadopoulou K, Zagouri F, Christodoulou C, Koutras A, Makatsoris T, Chrisafi S, Linardou H, Varthalitis I, Papatsibas G, Razis E, Papakostas P, Samantas E, Aravantinos G, Bafaloukos D, Kosmidis P, Koumarianou A, Psyri A, Pentheroudakis G, Pectasides D, Futreal A, Fountzilas G, Tsimberidou AM. Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. *Oncotarget*. 2020 Jan 7;11(1):1-14. doi: 10.18632/oncotarget.27338. PMID: 32002119; PMCID: PMC6967777.

70: Papadopoulou E, Tsoulos N, Tsantikidi K, Metaxa-Mariatou V, Stamou PE, Kladi-Skandali A, Kapeni E, Tsaousis G, Pentheroudakis G, Petrakis D, Lampropoulou DI, Aravantinos G, Varthalitis I, Kesisis G, Boukovinas I, Papakotoulas P, Katirtzoglu N, Athanasiadis E, Stavridi F, Christodoulou C, Koumarianou A, Eralt Y, Nasioulas G. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients. *PLoS One*. 2019 Dec 20;14(12):e0226853. doi: 10.1371/journal.pone.0226853. PMID: 31860648; PMCID: PMC6924668.

71: Fountoulakis A, Souglakos J, Vini L, Douridas GN, Koumarianou A, Kountourakis P, Agalianos C, Alexandrou A, Dervenis C, Gourtsoyianni S, Gouvas N, Kalogeridi MA, Levidou G, Liakakos T, Sgouros J, Sgouros SN, Triantopoulou C, Xynos E. Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer. *Updates Surg*. 2019 Dec;71(4):599-624. doi: 10.1007/s13304-019-00696-3. Epub 2019 Dec 2. PMID: 31792842.

72: Chatzellis E, Daskalakis K, Angelousi A, Tsoli M, Alexandraki KI, Wachula E, Meirovitz A, Maimon O, Grozinsky-Glasberg S, Gross D, Kos-Kudła B, Koumarianou A, Kaltsas G. Authors' Response to the Letter by Lamarca et al. Entitled "Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration" Regarding "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms". *Neuroendocrinology*. 2020;110(1-2):158-160. doi: 10.1159/000503999. Epub 2019 Oct 10. PMID: 31597137.

73: Tsoli S, Galanakis M, Koumarianou A, Makris G, Kapogiannis A, Chrousos G. Validation of the Patient Empowerment Strategies Questionnaire (PES-Q) in Greek adult patients with chronic insomnia: a pilot study on basic psychometric values. *Prim Health Care Res Dev*. 2019 Sep 12;20:e130. doi: 10.1017/S1463423619000616. PMID: 31511115; PMCID: PMC6749550.

74: Duran-Moreno J, Kampoli K, Kapetanakis EI, Mademli M, Koufopoulos N, Foukas PG, Kostopanagiotou K, Tomos P, Koumarianou A. Pericardial Synovial Sarcoma: Case Report, Literature Review and Pooled Analysis. In *Vivo*. 2019 Sep-Oct;33(5):1531-1538. doi: 10.21873/in vivo.11633. PMID: 31471401; PMCID: PMC6754991.

75: Kampoli K, Gardeli D, Mouktaroudi M, Fanouriakis A, Lazaris AM, Koumarianou A. Paraneoplastic digital ischemia in clear-cell renal-cell carcinoma: Report of a case and review of the literature. *Urologia*. 2019 Aug;86(3):156-160. doi: 10.1177/0391560318761289. Epub 2018 Apr 1. PMID: 31431168.

76: Duran-Moreno J, Kontogeorgakos V, Koumarianou A. Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes. *Oncol Lett*. 2019 Sep;18(3):2179-2191. doi: 10.3892/ol.2019.10575. Epub 2019 Jul 5. PMID: 31404317; PMCID: PMC6676724.

77: Ntavatzikos A, Spathis A, Patapis P, Machairas N, Vourli G, Peros G, Papadopoulos I, Panayiotides I, Koumarianou A. TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer. *World J Gastrointest Oncol*. 2019 Jul 15;11(7):551-566. doi: 10.4251/wjgo.v11.i7.551. PMID: 31367274; PMCID: PMC6657223.

78: Papanastasiou A, Seliniotaki T, Rizos E, Kampoli K, Ntavatzikos A, Arkadopoulos N, Tsionou C, Spandidos DA, Koumarianou A. Role of stress, age and adjuvant therapy in the cognitive function of patients with breast cancer. *Oncol Lett*. 2019 Jul;18(1):507-517. doi: 10.3892/ol.2019.10361. Epub 2019 May 15. PMID: 31289522; PMCID: PMC6540331.

79: Chatzellis E, Angelousi A, Daskalakis K, Tsoli M, Alexandraki KI, Wachula E, Meirovitz A, Maimon O, Grozinsky-Glasberg S, Gross D, Kos-Kudła B, Koumarianou A, Kaltsas G. Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced

Neuroendocrine Neoplasms. *Neuroendocrinology*. 2019;109(4):333-345. doi: 10.1159/000500135. Epub 2019 Jun 3. PMID: 31167197.

80: Tsaousis GN, Papadopoulou E, Apessos A, Aghiannitopoulos K, Pepe G, Kampouri S, Diamantopoulos N, Floros T, Iosifidou R, Katopodi O, Koumariou A, Markopoulos C, Papazisis K, Venizelos V, Xanthakis I, Xepapadakis G, Banu E, Eniu DT, Negru S, Stanculeanu DL, Ungureanu A, Ozmen V, Tansan S, Tekinel M, Yalcin S, Nasioulas G. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations. *BMC Cancer*. 2019 Jun 3;19(1):535. doi: 10.1186/s12885-019-5756-4. PMID: 31159747; PMCID: PMC6547505.

81: Daskalakis K, Tsoli M, Angelousi A, Kassi E, Alexandraki KI, Kolomodi D, Kaltsas G, Koumariou A. Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms. *Endocr Connect*. 2019 Jun;8(6):641-653. doi: 10.1530/EC-19-0134. PMID: 31026812; PMCID: PMC6528409.

82: Anestis A, Sarantis P, Theocharis S, Zoi I, Tryfonopoulos D, Korogiannos A, Koumariou A, Xingi E, Thomaidou D, Kontos M, Papavassiliou AG, Karamouzis MV. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer. *J Cancer Res Clin Oncol*. 2019 May;145(5):1221-1233. doi: 10.1007/s00432-019-02872-9. Epub 2019 Feb 25. PMID: 30805773.

83: Tsoli M, Chatzellis E, Koumariou A, Kolomodi D, Kaltsas G. Current best practice in the management of neuroendocrine tumors. *Ther Adv Endocrinol Metab*. 2018 Oct 31;10:2042018818804698. doi: 10.1177/2042018818804698. PMID: 30800264; PMCID: PMC6378464.

84: Koumariou A, Krivan S, Machairas N, Ntavatzikos A, Pantazis N, Schizas D, Martikos G, Kampoli K, Misiakos EP, Patapis P, Liakakos T. Ten-year survival outcomes of patients with potentially resectable gastric cancer: impact of clinicopathologic and treatment-related risk factors. *Ann Gastroenterol*. 2019 Jan-Feb;32(1):99-106. doi: 10.20524/aog.2018.0320. Epub 2018 Oct 3. PMID: 30598599; PMCID: PMC6302201.

85: Syrios J, Pappa E, Volakakis N, Grivas A, Alafis J, Manioudaki S, Tzouda V, Korogiannos A, Rapti C, Koufopoulos N, Nikolaidou A, Kanavou E, Alexopoulos A, Koumariou A. Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab. *Breast Cancer (Auckl)*. 2018 Feb 20;12:1178223418758031. doi: 10.1177/1178223418758031. PMID: 29511355; PMCID: PMC5826003.

86: Kapetanakis EI, Sidiropoulou T, Koumariou A, Kostopanagiotou K, Tomos P. Delivering quality lung cancer care in crisis-wracked Greece. *J Surg Oncol*. 2018 Mar;117(3):537-538. doi: 10.1002/jso.24874. Epub 2017 Nov 22. PMID: 29165818.

87: Tsoulos N, Papadopoulou E, Metaxa-Mariatou V, Tsaousis G, Efstathiadou C, Tounta G, Scapeti A, Bourkoula E, Zarogoulidis P, Pentheroudakis G, Kakolyris S, Boukovinas I, Papakotoulas P, Athanasiadis E, Floros T, Koumariou A, Barbounis V, Dinischioti A, Nasioulas G. Tumor molecular profiling of NSCLC patients using next generation sequencing. *Oncol Rep*. 2017 Dec;38(6):3419-3429. doi: 10.3892/or.2017.6051. Epub 2017 Oct 23. PMID: 29130105; PMCID: PMC5783588.

88: Ntavatzikos A, Spathis A, Patapis P, Machairas N, Peros G, Konstantoudakis S, Leventakou D, Panayiotides IG, Karakitsos P, Koumariou A. Integrating *TYMS*, *KRAS* and *BRAF* testing in patients with metastatic colorectal cancer. *World J Gastroenterol*. 2017 Aug 28;23(32):5913-5924. doi: 10.3748/wjg.v23.i32.5913. PMID: 28932083; PMCID: PMC5583576.

89: Angelousi A, Kaltsas G, Koumariou A, Weickert MO, Grossman A. Chemotherapy in NETs: When and how. *Rev Endocr Metab Disord*. 2017 Dec;18(4):485-497. doi: 10.1007/s11154-017-9432-1. PMID: 28890993.

90: Misiakos EP, Damaskou V, Koumariou A, Gouloumi AR, Patapis P, Zavras N, Machairas A. A giant squamous cell carcinoma of the skin of the thoracic wall: a case report and review of the literature. *J Med Case Rep*. 2017 May 11;11(1):136. doi: 10.1186/s13256-017-1281-8. PMID: 28494816; PMCID: PMC5426016.

91: Pelekasis P, Kampoli K, Ntavatzikos A, Charoni A, Tsionou C, Koumariou A. Depressive symptoms during adverse economic and political circumstances: A comparative study on Greek female breast cancer patients receiving chemotherapy treatment. *Eur J Cancer Care (Engl)*. 2017 Nov;26(6). doi: 10.1111/ecc.12687.

Epub 2017 Apr 11. PMID: 28398649.

92: Pelekasis P, Matsouka I, Koumarianou A. Progressive muscle relaxation as a supportive intervention for cancer patients undergoing chemotherapy: A systematic review. *Palliat Support Care*. 2017 Aug;15(4):465-473. doi: 10.1017/S1478951516000870. Epub 2016 Nov 28. PMID: 27890023.

93: Zavras N, Siristatidis C, Siatelis A, Koumarianou A. Fertility Risk Assessment and Preservation in Male and Female Prepubertal and Adolescent Cancer Patients. *Clin Med Insights Oncol*. 2016 Jun 28;10:49-57. doi: 10.4137/CMO.S32811. PMID: 27398041; PMCID: PMC4927042.

94: Fragkou P, Souli M, Theochari M, Kontopoulou C, Loukides S, Koumarianou A. A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab. *Drug Target Insights*. 2016 May 22;10:9-12. doi: 10.4137/DTI.S31565. PMID: 27257369; PMCID: PMC4877140.

95: Koumarianou A, Kontopoulou C, Kouloulis V, Tsionou C. Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain. *Case Rep Oncol Med*. 2016;2016:5718104. doi: 10.1155/2016/5718104. Epub 2016 Apr 18. PMID: 27195161; PMCID: PMC4852335.

96: Nikou GC, Pazaitou-Panayiotou K, Dimitroulopoulos D, Alexandrakis G, Papakostas P, Vaslamatzis M, Kaldrymidis P, Markussis V, Koumarianou A; "G-NET-Registry" investigators. Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients. *BMC Endocr Disord*. 2016 Feb 12;16:8. doi: 10.1186/s12902-016-0089-7. PMID: 26872616; PMCID: PMC4752769.

97: Pelekasis P, Zisi G, Koumarianou A, Marioli A, Chrousos G, Syrigos K, Darviri C. Forming a Stress Management and Health Promotion Program for Women Undergoing Chemotherapy for Breast Cancer: A Pilot Randomized Controlled Trial. *Integr Cancer Ther*. 2016 Jun;15(2):165-74. doi: 10.1177/1534735415598225. Epub 2015 Aug 4. PMID: 26242890; PMCID: PMC5736052.

98: Koumarianou A, Economopoulou P, Katsaounis P, Laschos K, Arapantoni-Dadioti P, Martikos G, Rogdakis A, Tzanakis N, Boukovinas I. Gastrointestinal Stromal Tumors (GIST): A Prospective Analysis and an Update on Biomarkers and Current Treatment Concepts. *Biomark Cancer*. 2015 May 21;7(Suppl 1):1-7. doi: 10.4137/BIC.S25045. PMID: 26056505; PMCID: PMC4454203.

99: Koumarianou A, Karayannopoulou G, Gourgioti G, Batistatou A, Bobos M, Efstratiou I, Miliaras D, Galani E, Pentheroudakis G, Pectasides D, Aravantinos G, Bafaloukos D, Papakostas P, Razis E, Kalofonos HP, Petraki K, Sotiropoulou M, Kalogeras KT, Fountzilas G. PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients. *Cancer Chemother Pharmacol*. 2015 Jun;75(6):1289-301. doi: 10.1007/s00280-015-2762-3. Epub 2015 May 7. PMID: 25947084.

100: Koumarianou A, Kaltsas G, Kulke MH, Oberg K, Strosberg JR, Spada F, Galdy S, Barberis M, Fumagalli C, Berruti A, Fazio N. Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects. *Neuroendocrinology*. 2015;101(4):274-88. doi: 10.1159/000430816. Epub 2015 Apr 29. PMID: 25924937.

101: Koumarianou A, Tzeveleki I, Mekras D, Eleftheraki AG, Bobos M, Wirtz R, Fountzilas E, Valavanis C, Xanthakis I, Kalogeras KT, Basdanis G, Pentheroudakis G, Kotoula V, Fountzilas G. Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression. *Anticancer Res*. 2014 Sep;34(9):4949-62. PMID: 25202077.

102: Koumarianou A, Christodoulou MI, Patapis P, Papadopoulos I, Liakata E, Giagini A, Stavropoulou A, Poulakaki N, Tountas N, Xiros N, Economopoulos T, Pectasides D, Tsitsilonis OE, Pappa V. The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients. *Exp Hematol Oncol*. 2014 Jan 23;3(1):3. doi: 10.1186/2162-3619-3-3. PMID: 24456704; PMCID: PMC3906764.

103: Koumarianou A, Oikonomopoulou P, Baka M, Vlachodimitropoulos D, Argentos S, Piperos T, Christodoulou MI, Theodoulou K, Mariolis-Sapsakos T. Implications of the Incidental Finding of a MYCN Amplified Adrenal Tumor: A Case Report and

Update of a Pediatric Disease Diagnosed in Adults. Case Rep Oncol Med. 2013;2013:393128. doi: 10.1155/2013/393128. Epub 2013 Dec 11. PMID: 24396620; PMCID: PMC3874313.

104: Konialis C, Savola S, Karapanou S, Markaki A, Karabela M, Polychronopoulou S, Ampatzidou M, Voulgarelis M, Viniou NA, Variami E, Koumarianou A, Zoi K, Hagrefelt B, Schouten JP, Pangalos C. Routine application of a novel MLPA-based first-line screening test uncovers clinically relevant copy number aberrations in haematological malignancies undetectable by conventional cytogenetics. Hematology. 2014 Jun;19(4):217-24. doi: 10.1179/1607845413Y.0000000112. Epub 2013 Nov 25. PMID: 23928116.

105: Koumarianou A, Chatzellis E, Boutzios G, Tsavaris N, Kaltsas G. Current concepts in the diagnosis and management of poorly differentiated gastrointestinal neuroendocrine carcinomas. Endokrynol Pol. 2013;64(1):60-72. PMID: 23450449.

106: Koumarianou A, Kaltsas G. Bevacizumab plus temozolomide: a novel treatment option for advanced neuroendocrine tumors? J Clin Oncol. 2013 Mar 1;31(7):975-6. doi: 10.1200/JCO.2012.45.7523. Epub 2013 Jan 28. PMID: 23358970.

107: Fountzilas G, Christodoulou C, Bobos M, Kotoula V, Eleftheraki AG, Xanthakis I, Batistatou A, Pentheroudakis G, Xiros N, Papaspirou I, Koumarianou A, Papakostas P, Bafaloukos D, Skarlos DV, Kalogeras KT. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. J Transl Med. 2012 Oct 23;10:212. doi: 10.1186/1479-5876-10-212. PMID: 23092535; PMCID: PMC3499161.

108: Rizos E, Siafakas N, Koumarianou A, Katsantoni E, Filippopoulou A, Ntounas P, Touloumis Ch, Kastania A, Zoumpourlis V. miR-183 as a molecular and protective biomarker for cancer in schizophrenic subjects. Oncol Rep. 2012 Dec;28(6):2200-4. doi: 10.3892/or.2012.2052. Epub 2012 Sep 21. PMID: 23007659.

109: Papatsimpas G, Kamposioras K, Goula K, Papaparaskeva K, Loukides S, Kotoulas C, Kelekis N, Xiros N, Pectasides D, Koumarianou A. Hepatoid pancoast tumor. A case report and review of the literature. Lung Cancer. 2012 Aug;77(2):239-45. doi: 10.1016/j.lungcan.2012.05.102. Epub 2012 Jun 5. PMID: 22677427.

110: Koumarianou A, Karageorgopoulou S, Machairas A, Liakakos T, Chranioti S, Dimitriadis G, Misiakos EP. A pleomorphic rhabdomyosarcoma mimicking an inguinal hernia: a case report and review of the literature. Case Rep Oncol. 2012 Jan;5(1):74-9. doi: 10.1159/000336158. Epub 2012 Feb 4. PMID: 22611365; PMCID: PMC3355653.

111: Zygogianni AG, Kyrgias G, Psyrri A, Kantzou I, Koumarianou A, Tolia M, Tsekeris P, Tsirigotis P, Sarris G, Kouvaris J, Kouloulas V. Radiotherapy for Hodgkin's lymphoma: too hard to die? J BUON. 2012 Jan-Mar;17(1):116-23. PMID: 22517704.

112: Koumarianou A, Antoniou S, Kanakis G, Economopoulos N, Rontogianni D, Ntavatzikos A, Tsavaris N, Pectasides D, Dimitriadis G, Kaltsas G. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr Relat Cancer. 2012 Jan 9;19(1):L1-4. doi: 10.1530/ERC-11-0287. PMID: 22232542; PMCID: PMC3255566.

113: Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos FI, Koumarianou A, Varthalitis I, Fostira F, Sgouros J, Briasoulis E, Bournakis E, Bafaloukos D, Bompolaki I, Galani E, Kalogeras KT, Pectasides D, Fountzilas G, Kalofonos HP. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J. 2012 Dec;12(6):468-75. doi: 10.1038/tpj.2011.37. Epub 2011 Aug 16. PMID: 21844885.

114: Avgerinos ED, Moulakakis K, Brountzos E, Giannakopoulos TG, Lazaris AM, Koumarianou A, Geronikola-Trapali X, Ptohis N, Papapetrou A, Liapis CD. Advances in assessment and management of carotid body tumors. Vascular. 2011 Oct;19(5):250-6. doi: 10.1258/vasc.2011.0a0291. Epub 2011 Aug 15. PMID: 21844248.

115: Karamitopoulou E, Zlobec I, Koumarianou A, Patsouris ES, Peros G, Lugli A.

Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups: a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases. *Cancer*. 2010 Oct 1;116(19):4474-86. doi: 10.1002/cncr.25304. PMID: 20572035.

116: Pectasides D, Pectasides E, Papaxoinis G, Psyrris A, Pliarchopoulou K, Koumariou A, Macheras A, Athanasas G, Xiros N, Economopoulos T. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma. *Gynecol Oncol*. 2010 Jul;118(1):52-7. doi: 10.1016/j.ygyno.2010.03.003. Epub 2010 Apr 20. PMID: 20406710.

117: Koumariou A, Fountzilas G, Kosmidis P, Klouvas G, Samantas E, Kalofonos C, Pentheroudakis G, Economopoulos T, Pectasides D. Non small cell lung cancer in the elderly: clinico-pathologic, management and outcome characteristics in comparison to younger patients. *J Chemother*. 2009 Nov;21(5):573-83. doi: 10.1179/joc.2009.21.5.573. PMID: 19933050.

118: Pectasides D, Fountzilas G, Papaxoinis G, Pectasides E, Xiros N, Sykietis C, Koumariou A, Psyrris A, Panayiotides J, Economopoulos T. Carboplatin and paclitaxel in metastatic or recurrent cervical cancer. *Int J Gynecol Cancer*. 2009 May;19(4):777-81. doi: 10.1111/IGC.0b013e3181a40a8b. PMID: 19509587.

119: Pectasides D, Pectasides E, Papaxoinis G, Koumariou A, Psyrris A, Xiros N, Tountas N, Kamposioras K, Papatsibas G, Floros T, Gouveris P, Karageorgopoulou S, Economopoulos T. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience. *Anticancer Res*. 2009 Feb;29(2):769-75. PMID: 19331234.

120: Pectasides D, Pectasides E, Papaxoinis G, Skondra M, Gerostathou M, Karageorgopoulou S, Kamposioras C, Tountas N, Koumariou A, Psyrris A, Macheras A, Economopoulos T. Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy. *J Androl*. 2009 May-Jun;30(3):280-6. doi: 10.2164/jandrol.108.006437. Epub 2009 Jan 8. PMID: 19136393.

121: Pectasides D, Nikolaou M, Pectasides E, Koumariou A, Valavanis C, Economopoulos T. Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma. *Anticancer Res*. 2008 Jul-Aug;28(4C):2317-20. PMID: 18751412.

122: Koumariou A, Kountourakis P, Economopoulos T. Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma. *J Steroid Biochem Mol Biol*. 2008 Apr;109(3-5):230-2. doi: 10.1016/j.jsbmb.2008.03.008. Epub 2008 Mar 7. PMID: 18406604.

123: Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykietis C, Koumariou A, Psyrris A, Gaglia A, Kassanos D, Gouveris P, Panayiotides J, Fountzilas G, Economopoulos T. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. *Gynecol Oncol*. 2008 May;109(2):250-4. doi: 10.1016/j.ygyno.2008.01.028. Epub 2008 Mar 4. PMID: 18299146.

124: Pectasides D, Xiros N, Papaxoinis G, Aravantinos G, Sykietis C, Pectasides E, Psyrris A, Koumariou A, Gaglia A, Gouveris P, Economopoulos T. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma. *Gynecol Oncol*. 2008 Jan;108(1):47-52. doi: 10.1016/j.ygyno.2007.08.061. Epub 2007 Oct 25. PMID: 17915300.

125: Aninos D, Koumariou A, Georgoulakis J, Pektasidis D, Brountzos E, Zoumpoulis Ch, Economopoulos T, Karakitsos P. Liver metastasis of adenoid cystic carcinoma of salivary origin: report of a case prepared by ThinPrep method. *Cytopathology*. 2007 Aug;18(4):268-9. doi: 10.1111/j.1365-2303.2006.00405.x. PMID: 17635167.

126: Koumariou AA, Xiros N, Papageorgiou E, Pectasides D, Economopoulos T. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades. *Anticancer Res*. 2007 Mar-Apr;27(2):1191-7. PMID: 17465262.

127: Pectasides D, Pectasides M, Psyrris A, Koumariou A, Xiros N, Pectasides E,

Gaglia A, Lianos E, Papaxoinis G, Lampadiari V, Economopoulos T. Cisplatin-based chemotherapy for merkel cell carcinoma of the skin. *Cancer Invest.* 2006 Dec;24(8):780-5. doi: 10.1080/07357900601062354. PMID: 17162559.

128: Fohrer C, Caillard S, Koumarianou A, Ellero B, Woehl-Jaeglé ML, Meyer C, Epailly E, Chenard MP, Lioure B, Natarajan-Ame S, Maloisel F, Lutun P, Kessler R, Moulin B, Bergerat JP, Wolf P, Herbrecht R. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. *Br J Haematol.* 2006 Sep;134(6):602-12. doi: 10.1111/j.1365-2141.2006.06228.x. Epub 2006 Aug 2. PMID: 16889621.

129: Pectasides D, Farmakis D, Koumarianou A. The role of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer. *Oncology.* 2005;68(1):64-70. doi: 10.1159/000084822. Epub 2005 Mar 8. PMID: 15809522.

130: Pectasides D, Pectasides M, Farmakis D, Gaglia A, Koumarianou A, Nikolaou M, Koumpou M, Kountourakis P, Papaxoinis G, Mitrou P, Economopoulos T, Raptis SA. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. *Gynecol Oncol.* 2004 Oct;95(1):165-72. doi: 10.1016/j.ygyno.2004.06.029. PMID: 15385127.

131: Maloisel F, Andrès E, Zimmer J, Noel E, Zamfir A, Koumarianou A, Dufour P. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. *Am J Med.* 2004 May 1;116(9):590-4. doi: 10.1016/j.amjmed.2003.12.024. PMID: 15093754.

132: Zimmer J, Andrès E, Noel E, Koumarianou A, Blicklé JF, Maloisel F. Current management of adult idiopathic thrombocytopenic purpura in practice: a cohort study of 201 patients from a single center. *Clin Lab Haematol.* 2004 Apr;26(2):137-42. doi: 10.1111/j.1365-2257.2004.00591.x. PMID: 15053808.

133: Andrès E, Zimmer J, Noel E, Kaltenbach G, Koumarianou A, Maloisel F. Idiopathic thrombocytopenic purpura: a retrospective analysis in 139 patients of the influence of age on the response to corticosteroids, splenectomy and danazol. *Drugs Aging.* 2003;20(11):841-6. doi: 10.2165/00002512-200320110-00005. PMID: 12964890.

134: Maloisel F, Andrès E, Kaltenbach G, Noel E, Koumarianou A. Prognostic factors of hematologic recovery in nonchemotherapy drug-induced agranulocytosis. *Haematologica.* 2003 Apr;88(4):470-1. PMID: 12681976.

135: Tsirigotis P, Economopoulos T, Rontogianni D, Dervenoulas J, Papageorgiou E, Bolas G, Mantzios G, Kalantzis D, Koumarianou A, Raptis S. T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma. *Oncology.* 2001;61(4):257-64. doi: 10.1159/000055331. PMID: 11721171.

136: Dervenoulas J, Tsirigotis P, Bolas G, Koumarianou AA, Pappa V, Mantzios G, Xiros N, Economopoulos T, Papageorgiou E, Pappa M, Raptis SA. Efficacy of intravenous immunoglobulin in the treatment of thrombotic thrombocytopenic purpura. A study of 44 cases. *Acta Haematol.* 2001;105(4):204-8. doi: 10.1159/000046567. PMID: 11528094.

137: Maloisel F, Andrès E, Campos F, Opréa C, Deslandres M, Randriamahazaka R, Kurtz JE, Koumarianou A, Dufour P. Y a-t-il une place pour l'interféron-alpha dans la stratégie thérapeutique de la maladie de Castleman multicentrique? [Is there a place for interferon-alpha in the treatment strategy of multicentric Castleman's disease?]. *Rev Med Interne.* 2000 May;21(5):435-8. French. doi: 10.1016/s0248-8663(00)88954-7. PMID: 10874763.

138: Koumarianou AA, Hudson M, Williams R, Epenetos AA, Stamp GW. Development of a novel bi-specific monoclonal antibody approach for tumour targeting. *Br J Cancer.* 1999 Oct;81(3):431-9. doi: 10.1038/sj.bjc.6690712. PMID: 10507767; PMCID: PMC2362912.

139: Lalani EN, Williams R, Jayaram Y, Gilbert C, Chaudhary KS, Siu LS, Koumarianou A, Playford R, Stamp GW. Trefoil factor-2, human spasmodic polypeptide, promotes branching morphogenesis in MCF-7 cells. *Lab Invest.* 1999 May;79(5):537-46. PMID: 10334565.

140: Koumarianou AA, Vernon CC. Second primary renal cell carcinomas following

solid tumors. Four case reports and review of the literature. *Tumori*. 1998 Sep-Oct;84(5):600-2. doi: 10.1177/030089169808400517. PMID: 9862524.

141: Papageorgiou PP, Koumarianou AA, Chu AC. Pigmented Bowen's disease. *Br J Dermatol*. 1998 Mar;138(3):515-8. doi: 10.1046/j.1365-2133.1998.02136.x. PMID: 9580811.

Chapters in Books:

- Koumarianou A., Fazio N. (2024). Non-Functioning Pancreatic Neuroendocrine Tumors. In: Yalcin, S., Öberg, K. (eds) *Neuroendocrine Tumours*. Springer, Cham. <https://doi.org/10.1007/978-3-031-56968-5>.
 - Non-Functioning Pancreatic Neuroendocrine Tumors (Chapter 18)
 - Overview of Functioning Pancreatic Neuroendocrine Tumors (F-panNETs) (Chapter 11).
- Koumarianou A. The treatment of large cell neuroendocrine tumors of the lung. In *Updates in the treatment of Lung Cancer*. Evangelismos Hospital Publications 2012 (chapter 8).

Abstracts in International Conferences 2024:

1. Efficacy of immune checkpoint inhibitors in patients with advanced pancreatic NETs displaying high TMB and MMR alterations following treatment with alkylating agents. Jonathan R Strosberg, Anna Koumarianou, Rachel Riechelmann, Jorge Hernando, Sara Cingarlini, Joakim Crona, Taymeh E Al-Toubah, Leonidas Apostolidis, Emily K Bergsland, Thorvardur Ragnar Halfdanarson, Jerome Cros, Louis De Mestier DU Bourg. *Journal of Clinical Oncology American Society of Clinical Oncology. ASCO GI meeting 2025*.
2. 94P Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first-line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study. D Ziogas, H Linardou, A Charpidou, A Koumarianou, G Mountzios, P Kosmidis, C Christodoulou, D Mavroudis, AN Christopoulou, I Korantzis, S Baka, M Vaslamatzis, I Athanasiadis, A Koutras, D Mauri, A Kotsakis, A Visvikis, F Spanoudi, T Tsihrizis, K Syrigos. *Immuno-Oncology and Technology*, Volume 24, 100837.
3. Georgakopoulos, A., Tsoli, M., Koumarianou, A., Papadopoulou, N., Panagaki, M., Kaltsas, G., & Chatziioannou, S. (2024, September). Significant Improvement of Quality of Life after first dose of Peptide Receptor Radionuclide Therapy (PRRT) in a Malignant Refractory Insulinoma: a Case Report Study. In *European Journal Of Nuclear Medicine And Molecular Imaging* (Vol. 51, Pp. S875-S875). One New York Plaza, Suite 4600, New York, Ny, United States: Springer.
4. 1858P Efficacy and safety of thromboprophylaxis in oncology patients with Khorana score<2: Combined results from GMat and ACT4CAT studies. NG Tsoukalas, AN Christopoulou, E Timotheadou, A Koumarianou, A Ardavanis, I Athanasiadis, M Demiri, A Bokas, GF Samelis, S Peroukidis, G Papatsimpas, C Andreadis, C Kalofonos, A Psyri, N Kapodistrias, P Papakostas, E Samantas, G Aravantinos, P Papakotoulas, I Boukovinas. *Annals of Oncology*, Volume 35, S1094
5. KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC. Vanesa Gregorc, Maria González-Cao, Stefania Salvagni, Anna Koumarianou, Ignacio Gil-Bazo, Michele Maio, Santiago Viteri, Margarita Majem, Vanesa Gutiérrez, Reyes Bernabe Caro, Miguel F Sanmamed, Huaqiang Zhu, Haige Shen, Yu Wang, Rafael Rosell. Poster and Oral Presentation at ASCO 2024. JCO 42, LBA8511-LBA8511(2024). DOI:10.1200/JCO.2024.42.17_suppl.LBA8511
6. 115P Exploratory analysis of angioregulatory microRNAs 27a, 27b, 107, and 622 in the progression of colorectal cancer. Koumarianou A, Damalas A, Ntavatzikos A, Kampoli K, Patapis P, Rogdakis A, Meimaris G, Foukas P, Arkadopoulos N. *Annals of Oncology*, Volume 35, S54
7. 33P Final Analysis of the Greek cohort of the AGENT Phase III study Arfolitixorin in Metastatic Colorectal Cancer. Koumarianou A, Bournakis E, Kotsakis A, Ntavatzikos A, Kampoli K, Kentepozidis N, Skintemo L, Tell R, Papadimitriou Ch. ESMO Gastrointestinal Congress. Munich, Germany, June 26-29, 2024. *Ann Oncol*, 2024; Volume 35, S17
8. 87P Real-World Evidence of FTD/TPI and Bevacizumab Combination Therapy in Metastatic Colorectal Cancer: Survival and Clinicopathological Insights. Koumarianou A, Ntavatzikos A, Symeonidis D, Vallilas Ch, Giannakakou M, Papaxoinis G, Xynogalos S, Boukovinas I, Demiri S, Kampoli K, Oikonomopoulos G, Samantas E, Res E, Androulakis N, Vourli G, Souglakos I, Karamouzis M. ESMO Gastrointestinal Congress. Munich, Germany, June 26-29, 2024. *Annals of Oncology*, Volume 35, S42 - S43
9. Safety and acceptance of nirmatrelvir/ritonavir in early SARS-CoV-2 treatment in Greek patients with solid cancer. Georgios Pappas, Nikolaos Tsoukalas, Anastasios L Boutis, Emmanouil S Saloustros, Ioanna Gazouli, Stefania Gkoura, Roubini Zakopoulou, Chrysovalantis Aidarinis, Ioannis Boukovinas, Anna Koumarianou, Stefania Kokkali, Georgios Gkoumas, Panagiotis J Vlachostergios, Avraam Assi, Athanasios Karampeazis, Adamantia Nikolaidi, Elena Fountzilias, Natalia Chatzifoti, Zacharenia Saridaki. Abstract ASCO 2024. JCO 42, e23139-e23139(2024). DOI:10.1200/JCO.2024.42.16_suppl.e23139.
10. 142TiP SARC-Digital: An observational, randomized, prospective study of the impact of digital health interventions on symptom and side-effect management in patients with metastatic sarcoma. S Kokkali-Zervos, J Durán Moreno, A Kyriazoglou, V Georgoulas, I Athanasiadis, A Koumarianou, NG Tsoukalas, V Ramfidis, A Stergioula, PA Kosmidis, DA Valoukas, D Tzanninis, G Varvaris, PT Baxevas, T Kosmidis, V Schoina, I Boukovinas. ESMO Sarcoma and

Rare Cancers Congress 2024 Lugano, Switzerland, 14-16 March, 2024. [https://www.esmoopen.com/article/S2059-7029\(24\)00335-1/fulltext](https://www.esmoopen.com/article/S2059-7029(24)00335-1/fulltext). Ann Oncol. 2024; 9 – (S2), p. 32 # 142TiP 2024

11. 90P Real-world data on immunotherapy in patients with soft tissue sarcoma: A study from the Hellenic Group of Sarcoma and Rare Cancers. S Kokkali-Zervos, A Kyriazoglou, A Koumariou, E Vorrias, N Asimakopoulou, A Boulouta, E Georgaki, AS Papadaki, A Stergioula, I Boukovinas. Ανακοινώθηκε στο ESMO Sarcoma and Rare Cancers Congress 2024. Lugano, Switzerland, 14-16 March, 2024. Annals of Oncol. 2024; 9 – (S2), p. 102479. DOI:<https://doi.org/10.1016/j.esmoop.2024.102479>. [https://www.esmoopen.com/article/S2059-7029\(24\)00247-3/fulltext](https://www.esmoopen.com/article/S2059-7029(24)00247-3/fulltext).
12. Real-world data on the safety and efficacy of trastuzumab deruxtecan and sacituzumab govitecan in patients with advanced breast cancer: the experience of the Hellenic Cooperative Oncology Group. E Fountzilas, T Lalla, G Karakatsoulis, K Papazisis, K Exarchos, A Koumariou, A Nikolaidi, I Binas, D Mauri, S Karageorgopoulou, E Razis, A Christopoulou, A Boutis, G Douganiotis, F Zagouri, S Stamatopoulou, N Spathas, D Tryfonopoulos, A Psyrri, A Koutras. 14th European Breast Cancer Conference (EBCC), Milan, Italy, 20-22 March, 2024. Eur J Cancer. 2024 Mar; 200 (Suppl. 1), p. 113954. DOI:<https://doi.org/10.1016/j.ejca.2024.113954>. [https://www.ejancer.com/article/S0959-8049\(24\)00179-5/abstract](https://www.ejancer.com/article/S0959-8049(24)00179-5/abstract)

Conferences organised

I am responsible for the organization of several National scientific meetings each year in Greece (data available on demand). As Advisory Board Member of the European Neuroendocrine Tumour Society (2019-2024) I participated as a member of the Educational Committee of ENETs (Postgraduate Course, Conference, Webinars).

Professional Memberships

Hellenic Society of Medical Oncology, Athens, Greece (since 2001)

General Medical Council, London, UK (since 1/12/1994). Currently not active member

Greek Medical Association, Athens, Greece (since 1992)

European Society of Medical Oncology (since 2003)

European Neuroendocrine Tumour Society (Since 2008)

Additional Information

Languages: Greek: (Native speaker); English (fluent); Italian (fluent); French (independent)

Computer Literacy: Microsoft Office

9th of February 2025



LETTERS OF RECOMMENDATIONS (Available on demand)

PROFESSOR GREGORY KALTSAS
PROFESSOR SOTIRIOS TSIODRAS
PROFESSOR ARISTOTELIS BAMIAS
PROFESSOR DIMITRIOS BOUMPAS